Shares of iBio Inc. IBIO inched 0.37% higher to $2.72 Wednesday, on what proved to be an all-around mixed trading session for ...

San Diego-based iBio has signed a backloaded agreement with its existing partner AstralBio for a preclinical anti-myostatin ...

Bio (IBIO) in collaboration with AstralBio announced the development of an antibody that inhibits the function of Activin E, a promising ...

On Thursday, iBio, Inc. (NYSE:IBIO) expanded its cardiometabolic and obesity treatment development program by in-licensing a ...

SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in ...

(RTTNews) - iBio, Inc. (IBIO), a preclinical stage biotechnology company, Thursday said it has in-licensed a long-acting anti-myostatin antibody, IBIO-600 from AstralBio, Inc. iBio has initiated a ...

Under this License Agreement, iBio will have exclusive rights, including sublicensing capabilities, for the development and commercialization of the product worldwide. In consideration for these ...

SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced the expansion of its cardiometabolic and ...

The state's life sciences industry has seen job growth of 7.5% since 2019, 20 times that of the overall private sector growth ...

Shares of iBio Inc. IBIO jumped 10.16% to $2.71 Tuesday, on what proved to be an all-around poor trading session for the ...

iBio in-licensed IBIO-600 from AstralBio for $750,000 in stock, with potential milestone payments of up to $28 million. IBIO-600 showed potent myostatin inhibition in preclinical studies ...

On Thursday, iBio, Inc. (NYSE:IBIO) expanded its cardiometabolic and obesity treatment development program by in-licensing a potentially long-acting anti-myostatin antibody from AstralBio ...